A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Launched by BAXALTA NOW PART OF SHIRE · Oct 12, 2016

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a treatment called recombinant von Willebrand Factor (rVWF), with or without another medication called ADVATE, for children under 18 years old who have severe von Willebrand Disease (VWD). VWD is a bleeding disorder that can make it difficult for the blood to clot properly. The trial aims to see how well rVWF works in managing bleeding events without surgery and to monitor any side effects that might occur during treatment.

To be eligible for the trial, participants must have a diagnosis of severe VWD and be aged between 0 and 17 years. They should also have had at least one bleeding episode in the past year that required replacement therapy. Throughout the study, which lasts 12 to 18 months, participants will receive treatment and will be regularly checked, either in person at clinics or through phone calls. This trial is currently recruiting participants, and it’s important for families to know that those who qualify will receive care tailored to their specific needs while contributing to valuable research on a condition that affects their health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Diagnosis of severe von Willebrand disease (VWD) (defined as von Willebrand factor: ristocetin cofactor \[VWF:RCo\] less than \[\<\] 20 percent \[%\]):
• • Type 1 (VWF:RCo \<20 International Units per deciliter \[IU/dL\]); or
• • Type 2A (VWF:RCo \<20 IU/dL), Type 2B (as diagnosed by genotype), Type 2N (Factor VIII coagulation activity \[FVIII:C\] \<10 % and historically documented genetics), Type 2M; or
• • Type 3 (VWF:Ag less than or equal to \[=\<\] 3 IU/dL).
• • Age 0 to \<18 years at the time of Screening.
• • The participant has provided assent (if appropriate) and legally authorized representative(s) has provided informed consent.
• • If female of childbearing potential, participant presents with a negative serum pregnancy test.
• • If applicable, participant agrees to employ adequate birth control measures for the duration of the study.
• • The participant and/or the legally authorized representative are willing and able to comply with the requirements of the protocol, which should also be confirmed based on a pre-screening evaluation held between the Investigator and the Sponsor, to ensure no eminent risk is present that could challenge the participants compliance with the study requirements.
• Additional inclusion criteria for both previously treated participants and participants undergoing surgery are as follows:
• • Unable to tolerate are inadequately responsive to, or not a good candidate for 1-deamino-8-D-arginine vasopressin (DDAVP). Examples of participants who are not good candidates for DDAVP include participants with type 2B or type 3 VWD.
• • The participant has had a minimum of 1 documented bleed requiring VWF coagulation factor replacement therapy (i.e. treatment with a VWF product) during the previous 12 months prior to enrollment and overall historically 3 or more exposure days (EDs) to VWF replacement therapy.
• Additional inclusion criterion for previously untreated participants are as follows:
• • - The participant has not received prior VWF coagulation factor replacement therapy.
• Exclusion Criteria:
• • Diagnosis of pseudo-VWD or another hereditary or acquired coagulation disorder (eg, qualitative and quantitative platelet disorders or elevated prothrombin time \[PT\]/international normalized ratio \[INR\] greater than \[\>\] 1.4).
• • History or presence of a VWF inhibitor at Screening.
• • History or presence of a Factor VIII (FVIII) inhibitor with a titer greater than or equal \[\>=\] 0.4 Bethesda units (BU) (by Nijmegen assay) or \>=0.6 BU (by Bethesda assay).
• • Documented history of a VWF: RCo half-life \<6 hours.
• • Known hypersensitivity to any of the components of the study drug, such as mouse or hamster proteins.
• • Medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis/asthma, food allergies, or animal allergies.
• • Medical history of a thromboembolic event.
• • Human immunodeficiency virus (HIV) positive, with an absolute CD4 count \<200/ cubic millimeter (mm\^3).
• • In the judgment of the Investigator, the participant has another clinically significant concomitant disease (e.g. uncontrolled hypertension, cancer) that may pose additional risks for the participant.
• • Diagnosis of significant liver disease, as evidenced by, but not limited to, any of the following: serum alanine aminotransferase (ALT) of 5 times the upper limit of normal; hypoalbuminemia; portal vein hypertension (e.g. presence of otherwise unexplained splenomegaly, history of esophageal varices) or liver cirrhosis classified as Child B or C.
• • Diagnosis of renal disease, with a serum creatinine level \>=2.5 milligram per deciliter (mg/dL).
• • Immunomodulatory drug treatment other than anti-retroviral chemotherapy (e.g. α-interferon, or corticosteroid agents at a dose equivalent to hydrocortisone greater than 10 milligram per day \[mg/day\] (excluding topical treatment \[e.g. ointments, nasal sprays\]), within 30 days prior to signing the informed consent (or assent, if appropriate).
• • If female, participant is pregnant or lactating at the time informed consent (or assent, if appropriate) is obtained.
• • Participant has participated in another clinical study involving an investigational product (IP), other than vonicog alfa with or without ADVATE, or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP other than vonicog alfa or investigational device during the course of this study.
• • Participant's legal representative is a family member or employee of the Investigator.